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A prospective multicenter observational study was undertaken on children and adults with epilepsy in whom
first monotherapy failed, to assess indications and effects of alternative monotherapy vs. polytherapy. Patients
were followed until 12-month remission, drug withdrawal, or up to 18 months. Monotherapy and polytherapy
were compared for patients' baseline features, indication, retention time, remission, adverse events (AE), quality
of life, and direct and indirect costs. Included were 157 men and 174 women, aged 2–86 years. Of the patients,
72.2% were switched to alternative monotherapy. Baseline treatment was changed for lack of efficacy (73.9%)
or adverse events (26.1%). Two hundred forty-three completed the study (remission: 175; 72.0%). Retention
time, hospital admissions, days off-work and off-school, and quality of life did not differ between the two
treatment groups. Patients were followed for 365.3 person-years. Three hundred eighty-three incident AEs
were reported by 46.4% of patients in monotherapy and 40.2% in polytherapy (serious AEs: 9.6% vs. 8.7%, mostly
nondrug-related).
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1. Introduction
About 50–70% of patients with newly diagnosed epilepsy achieve
complete seizure remission after starting antiepileptic drugs as mono-
therapy treatment [1–4]. For those who continue to have seizures, the
physician has two options, an alternative monotherapy (substitution)
or a combination therapy (add-on), which generally involves adding a
second drug to the current monotherapy. As randomized trials [5,6]
did not provide evidence of which strategy should be preferred, clinical
practice will presumably present various treatment patterns, as shown
by a collaborative survey on prescribing strategies in Mediterranean
countries [7] and a survey of expert opinions in the USA [8]. In this com-
plex scenario, with few exceptions [9,10], the utilization of “classical”
and “new” antiepileptic drugs is poorly understood. In addition, the
safety profile of several possible treatment schedules is practically un-
known. Finally, there is little or no information on how the different
treatment choices affect health-related quality of life (HRQOL) and se-
lected economic indices, such as costs of epilepsy care and consumption
of medical resources.
This prospective observational, noninterventional study was there-
fore designed to describe the treatment strategies after failure of the
first monotherapy in children and adults with epilepsy and the factors
that influence neurologists' decisions. The impact of the two options
(alternative monotherapy and polytherapy) on seizure remission,
HRQOL, and resource consumption in an Italian populationwith epilep-
sy in a “real-life” clinical setting is described.
2. Material and methods
This multicenter, pragmatic, prospective, observational (cohort) in-
vestigation was done in secondary and tertiary outpatient services in
Italy. To be eligible for inclusion, each patient had to be two years of
age or older, to have a diagnosis of epilepsy [11], to reside in the center's
catchment area, to have seizures that failed to respond to the first
monotherapy for epilepsy, to be compliant with the assigned treatment
andwith the study's instructions, and to sign written informed consent.
Excluded were patients using experimental drugs, receiving two or
more antiepileptic drugs (AEDs) concurrently or in sequence, or previ-
ously treated with AEDs for other clinical indications (e.g., pain relief
or psychiatric disorders).
Failing monotherapy was defined as either seizure recurrence de-
spite doses judged by the physician to be maximally tolerated and/or
adverse events requiring treatment withdrawal.
Two patient cohortswere defined at entry: alternativemonotherapy
and add-on therapy. The alternative monotherapy cohort included
patients switching to a different single AED among those approved for
monotherapy, and the add-on therapy cohort included patients in
whom a second AED was added to their current monotherapy. The
local investigators were instructed to include all eligible patients de-
serving treatment change at any time after a breakthrough seizure, a re-
port of adverse drug reactions, or any other reason, depending on the
clinician's decision. All conventional and locally approved newer AEDs
could be prescribed, according to their label. As there was no prejudice
for or against one of the two treatment strategies, we decided not to
influence the caring physician's choice at any time during the study.
Guidelines for treatment change were not imparted because they
were against our purpose to examine treatment decisions as they were
taken in clinical practice.
The choice of therapy and time and frequency of visits were based
on each patient's individual requirements. Each patient concluded the
study either after seizure remission (i.e., no seizures for at least 12
consecutive months), when the assigned treatment failed (i.e., it was
withdrawn for any medical reason, which included inadequate seizure
control and/or unbearable adverse events requiring modification other
than dose adjustment), or after 18 months, whichever time point was
reached first.
At admission, patients (or, where indicated, their caregivers) were
interviewed for the collection of demographics and clinical data (date of
first seizure, date of diagnosis, seizure type(s) [12], etiology, epileptic syn-
drome [13], comorbidities, concurrent nonantiepileptic treatments). De-
tails of the first monotherapy (drug, daily dose, and any adverse events)
were collected in ad hoc semistructured forms, with the reason(s) for
changing treatment (i.e., efficacy and/or tolerability) and the new treat-
ment choice. The new treatment was also recorded, with details on
the AED, daily dose, and schedule of tapering. Each adverse event was
coded according to the MedDra dictionary [14]. Adverse events were
coded as either prevalent (present at study entry) or incident (occurring
during follow-up). Any laboratory or instrumental investigation deemed
necessary by the physician was also recorded and coded as an adverse
event if abnormal.
At study entry, the QOLIE-31 inventory (a validated measure of
HRQOL) [15] was administered to patients aged 18 years or older. At
each subsequent visit, a follow-up formwas completed by the physician,
recording information regarding the interval from the previous visit. The
form included the reason of the visit, a record of any recurrent seizure,
adverse event, and action taken since the previous visit (laboratory
tests, EEG tracings, imaging records, hospital admissions, outpatient
visits, and treatment changes, with reasons and details). An “End-of-
Study” form was used at the close of the study or when a patient with-
drew from the assigned treatment strategy, if that came first. Reasons
for withdrawal were recorded. Between visits, patients (or their care-
givers) reported details of seizures, adverse events, andmedical resource
consumption on ad hoc daily diaries. The physician examined the in-
formation in the diaries at follow-up visit and checked it for quality/
completeness. For those with incomplete or missing information in the
diaries, data on seizure recurrence, adverse events, hospitalizations, out-
patient consultations, and days off work/off school were collected at the
time of the visit. At the end of follow-up, the QOLIE-31was administered
again.
The main endpoints included choice of treatment strategy (alter-
native monotherapy or add-on therapy) and, for each strategy, reten-
tion time (i.e., time elapsed from the start to the end of the study or to
treatment discontinuation), seizure remission, treatment failure for
recurring seizures, treatment failure for adverse events, medical re-
sources consumed (hospital admissions and outpatient consulta-
tions), prevalence and incidence of adverse events, number of cases
reporting days off work/off school, and QOLIE-31 total scores.
All thedata recordedwere entered into a standard computerized da-
tabase. Data analysis included descriptive statistics and univariate and
multivariate inferential analyses comparing alternative monotherapy
and add-on therapy, in general and for children and adults separately.
The statistical analysis plan included descriptive statistics of all the de-
mographic and clinical variables of the sample at entry by treatment
strategy, with details on AED schedules (with any changes) and adverse
events at baseline and during follow-up, survival analysis for retention
time (using Kaplan–Meier curves and log-rank test for comparisons),
and multivariate analysis (using Cox's proportional hazard model, ad-
justing for age, center, epileptic syndrome, comorbidities, concurrent
nonantiepileptic drugs, and other variables significant at univariate
analysis). Statistical significance was also tested using the chi-square
test for treatment failure, in general and separately for recurring seizures
and adverse events and for seizure remission. Multivariate analysis was
also used (for treatment failure and seizure remission separately) with a
logistic regression model, adjusting for age, center, epileptic syndrome,
comorbidities, concurrent nonantiepileptic drugs, and other variables
significant at univariate analysis.
Finally, the Student's t-test, the Mann–Whitney test, and repeated
measures analysis of variance (ANOVA) were used, as appropriate,
for adverse events (in general and by severity, attribution to treat-
ment, and outcome), the cumulative number of days off work/off
school, and the QOLIE-31 scores, depending on the distribution of the
data.
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Since this was an observational study, no formal sample size cal-
culation was required. A total of 500 children and adults were origi-
nally planned to be included. During the course of the study, the
recruitment rate was slower than expected. For this reason, consider-
ing the time of enlistment, the minimum number was reduced to 300
patients.
The study was approved by the institutional review board at each
participating center.
3. Results
A total of 331 eligible patients from 58 centers were enrolled
from October 2005 through December 2006. The sample comprised
157 males (47.4%) and 174 females (52.6%) aged 2 to 86 years
(mean: 30.9, standard deviation (SD): 21.8). Table 1 lists the general
characteristics of the sample. There were 124 children aged less
than 18 years and 207 adults. The mean disease duration since
seizure onset was 68.5 months (SD: 96.4) with symptoms lasting
for more than 24 months in more than half of the cases (median:
29.4 months). Just over a third of the patients had a documented
etiology of their seizures. Among symptomatic epilepsies, brain tumors,
cerebrovascular disorders, structural malformations, and trauma were
the commonest underlying epileptogenic disorders. Valproate was the
commonest drug at baseline followedby carbamazepine, phenobarbital,
and oxcarbazepine.
Two hundred and thirty-nine patients were switched to an alterna-
tive monotherapy and 92 received an add-on treatment. The two
groups differed in time since seizure onset (mean [SD]: 63.3 [88.9]
months for alternative monotherapy and 81.8 [113.0] months for add-
on therapy; p b 0.01), number of seizure types, epilepsy syndromes,
and concomitant disorders (see Table 1). The commonest comorbidities
included arterial hypertension and cardiovascular disorders (42 cases),
diabetes and other endocrine/metabolic disorders (23 cases), congeni-
tal or developmental abnormalities (16 cases), and mental retardation
(14 cases). Compared to alternative monotherapy, patients receiving
add-on treatment had longer disease, more than one seizure type,
partial seizures, focal epilepsy, and lack of comorbidity. The median
number of seizures (with interquartile range) in the three months
preceding enrolment was 3 (0–10) in patients assigned alternative
monotherapy and 2 (1–4) in those assigned add-on therapy.
In the overall population, the initial monotherapy had to be changed
mainly because of the lack of efficacy (243 cases) followed by adverse
events (86 cases). In two cases, the change was required because of
the need to use an AED with effects on mood in one and in the other
for lack of effect and intolerable adverse events of monotherapy.
Treatment was discontinued because of adverse events more fre-
quently in adults (33.7%) than in children (13.7%) (p b 0.0001). In pa-
tients switched to an alternative monotherapy, the explanations were,
in decreasing order, better tolerability (143 cases, 59.8%), greater effica-
cy (63 cases, 26.4%), better tolerability and greater efficacy (17 cases,
7.1%), switch to a compound better suited to the individual case (10
cases, 4.2%), greater ease of use (5 cases, 2.1%), and patient's request
(1 case, 0.4%). Explanations did not differ for children and adults (data
not shown). In all patients receiving add-on therapy, the caring physi-
cian expected greater efficacy with the addition of a second drug than
with an alternative monotherapy.
Drugs assigned as alternative monotherapy differed from those
given as add-on therapy (Table 2). In patients switched to alternative
monotherapy, topiramate was the commonest drug, followed by carba-
mazepine, valproate, and oxcarbazepine. In patients receiving add-on
therapy, topiramate prevailed, followed by levetiracetam, valproate,
and carbamazepine. Significant differences in daily doses were seen
with lamotrigine and levetiracetam when given as monotherapy (see
Table 2).
Two hundred and forty-three patients (73.4%) completed the study.
Of these, 175 (52.9%) had 12-month seizure remission. The cumulative
time-dependent probability of remaining in the study was similar in
patients switched to alternative monotherapy and those receiving
add-on therapy (Fig. 1). Treatment failure was documented in 65 pa-
tients (27.2%) on monotherapy and 23 (25.0%) receiving two AEDs
(p = ns). The main reasons were lack of efficacy (monotherapy: 21
cases, 32.3%; add-on therapy: 11 cases, 47.8%) and adverse events
(monotherapy: 19 cases, 29.2%; add-on therapy: 6 cases, 26.1%)
(p = ns). The mean retention time was 454.4 days (SD: 11.1) for al-
ternative monotherapy and 447.4 days (SD: 16.4) for add-on thera-
py. Mean retention times were longer in adults than in children
(468.5 vs. 367.4 days, p = 0.08) but similarwhen comparing alternative
Table 1
General characteristics of the sample.
Variable Total
No. (%)
Alternative
monotherapy
No. (%)
Add-on
therapy
No. (%)
Sex
Male 174 (52.6) 130 (54.4) 44 (47.8)
Female 157 (47.4) 109 (45.6) 48 (52.2)
Age (years)
b18 124 (37.5) 87 (36.4) 37 (40.2)
>18 207 (62.5) 152 (63.6) 55 (57.8)
Disease duration (months)⁎⁎⁎
b12 99 (29.9) 83 (34.7) 16 (17.4)
13–24 48 (14.5) 31 (13.0) 17 (18.5)
>24 184 (55.6) 125 (52.3) 59 (64.1)
No. of seizure types⁎
1 233 (71.9) 174 (75.0) 59 (64.1)
2+ 91 (28.1) 58 (25.0) 33 (35.9)
NS 7 7
Seizure types
Partiala 229 (66.2) 156 (62.9) 73 (74.5)
Generalized 112 (32.4) 88 (35.5) 29 (24.5)
Other 5 (1.4) 4 (1.6) 1 (1.0)
Documented etiology
No 206 (62.5) 149 (62.3) 57 (63.0)
Yes 125 (37.5) 90 (37.7) 35 (37.0)
Neoplastic 23 (18.4) 15 (16.5) 8 (23.5)
Cerebrovascular 20 (16.0) 16 (17.6) 4 (11.8)
Structural malformation 18 (14.4) 14 (15.4) 4 (11.8)
Trauma 15 (12.0) 9 (9.9) 6 (17.7)
Degenerative 9 (7.2) 7 (7.7) 2 (5.9)
Perinatal encephalopathy 7 (5.6) 1 (1.1) 6 (17.7)
Infection 4 (3.2) 4 (4.4) 0
Metabolic 2 (1.6) 1 (1.1) 1 (2.9)
NS 27 (21.6) 24 (26.4) 3 (8.8)
Epilepsy syndrome⁎⁎
Focal 211 (63.9) 141 (59.0) 70 (76.9)
Generalized 97 (25.4) 80 (33.6) 17 (18.7)
Undetermined 16 (4.9) 14 (5.8) 2 (2.2)
Special 6 (1.8) 4 (1.8) 2 (2.2)
NS 1 1
Concomitant disorders⁎⁎
No 229 (69.2) 156 (65.3) 73 (79.4)
Yes 102 (30.8) 83 (34.7) 19 (20.6)
Monotherapy at baseline 108 (32.6) 75 (31.4) 33 (35.9)
Valproate 49 (14.8) 30 (12.6) 19 (20.7)
Carbamazepine 44 (13.3) 38 (15.9) 6 (6.6)
Phenobarbital 31 (9.4) 20 (8.4) 11 (12.0)
Topiramate 21 (6.3) 19 (8.0) 2 (2.2)
Phenytoin 20 (6.0) 15 (6.3) 5 (5.4)
Lamotrigine 10 (3.0) 8 (3.4) 2 (2.2)
Levetiracetam 8 (2.4) 8 (3.2) 0
Otherb
Other drugs (non-AEDs)
No 251 (75.5) 174 (72.8) 76 (82.6)
Yes 81 (24.5) 65 (27.2) 16 (17.4)
NS, not specified.
AEDs, antiepileptic drugs.
⁎ p b 0.05.
⁎⁎ p b 0.02.
⁎⁎⁎ p b 0.01.
a Include secondarily generalized seizures.
b Clobazam (2), clonazepam (1), diazepam (1), ethosuximide (2), gabapentin (1),
and sulthiame (1).
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monotherapy and add-on therapy in children and adults separately
(data not shown). The risk of leaving the study was higher for children
than for adults (hazard ratio (HR): 2.2; 95% CI: 1.1–4.4) and decreased
progressively with age (HR: 0.99 for each additional year; p b 0.05). Of
the 239 patients switched to alternative monotherapy, 128 (53.6%)
achieved 12-month seizure remission. The corresponding figure for the
92 patients receiving add-on therapywas 47 (51.1%) (p = ns). The like-
lihood of remission by treatment strategy was no different for children
and adults separately (data not shown).
A total of 129 prevalent adverse events (AEs) were reported by 94
patients (89 assigned subsequently to alternative monotherapy and
five to add-on therapy) (Table 3). Adverse events were more frequent
in adults than in children (36% vs. 15%). The commonest events were
nervous system disorders, followed by disorders of metabolism and
nutrition and dermatological disorders (Table 3). Only 13 adverse
events (10.1%) were severe. In 86 patients, AEs were considered
drug-related. During the study period, prevalent AEs resolved in the
majority of patients (77%).
Patients were followed for a total of 365.3 person-years. During this
period, 383 incident AEs were reported by 148 patients, 111 on alterna-
tive monotherapy and 37 on add-on therapy (incidence ratio: 1.03
per patient/year; 95% confidence interval (CI): 0.03–5.62). Adverse
events were considered drug-related in 56 patients (45 on alternative
monotherapy and 11 on add-on therapy). The incidence of AEs was
1.15 (95% CI: 0.04–5.83) with alternative monotherapy and 0.75 (95%
CI: 0.00–5.13) with add-on therapy.
Nervous system disorders were the commonest complaints with
a slight (nonsignificant) predominance in patients receiving alterna-
tive monotherapy, followed by gastrointestinal disorders, infections,
psychiatric disorders, and respiratory disorders (Table 4). Adverse
events with the highest cumulative incidence rate (i.e., between 1
and 2.3%) were associated with the use of phenobarbital (including
barbesaclone), clobazam, valproate, topiramate, and levetiracetam as
Table 2
Details on substituted/added AED and highest dose (mg/day) during follow-up by treat-
ment arm.
Alternative
monotherapy
(n = 239)
Add-on therapy
(n = 92)
Introduced drug Added drug Pre-existing drug
n (mg/day) n (mg/day) n (mg/day)
Barbexaclone 0 3 150.0 1 200.0
Carbamazepine 32 783.1 7 857.1 19 1036.8
Clobazam 1 20.0 2 20.0 0
Clonazepam 0 1 0.5 0
Ethosuximide 2 400.0 5 510.0 0
Phenytoin 2 375.0 1 400.0 2 325.0
Phenobarbital 1 100.0 6 100.0 5 125.0
Pregabalin 1 300.0 5 330.0 0
Lamotrigine⁎ 23 208.5 6 129.2 5 300.0
Levetiracetam⁎⁎ 21 1904.8 21 1404.8 2 2000.0
Oxcarbazepine 29 1044.8 4 975.0 14 1478.6
Topiramate 95 181.3 23 181.5 11 272.7
Valproate 32 793.8 8 818.7 33 909.1
⁎ p b 0.05.
⁎⁎ p b 0.02.
Fig. 1. Cumulative time-dependent probability of remaining in the study by treatment strategy.
Table 3
Patients with adverse events present at study entry (MedDra categories) in the entire
sample (N = 331).
Adverse event N %
Blood and lymphatic system 1 (0.3)
Endocrine
Gastrointestinal 6 (1.8)
General and injection site 4 (1.2)
Hepatobiliary 1 (0.3)
Immune system 1 (0.3)
Metabolism and nutrition 23 (6.9)
Musculoskeletal and connective tissue 4 (1.2)
Neoplasm 1 (0.3)
Nervous system 26 (7.8)
Psychiatric 8 (2.4)
Renal and urinary 4 (1.2)
Reproductive system and breast 4 (1.2)
Skin and subcutaneous tissue 13 (3.9)
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either monotherapy or add-on therapy, but in most cases, they were
considered to be unrelated to the medication. Most incident AEs
subsided during follow-up. A total of 30 patients (22 on alternative
monotherapy and 8 on add-on therapy) reported 37 serious adverse
events (28 in monotherapy and 9 in add-on therapy; 20 in adults and
17 in children), which, in most cases, were not drug-related. Serious
adverse events resolved in 35 instances and ended in death in two.
These two patients had symptomatic epilepsy caused, in one, by con-
genital hydrocephalus and, in the other, by a brain tumor. Severity
and outcome were no different in patients on alternative monotherapy
or add-on therapy.
A total of 160 patients (48.3%) completed the diaries; 28 (8.5% of
the entire sample) were hospitalized during the study. The median
(range) hospital stay was six days (1–25), was similar with alternative
monotherapy (median: 5; range: 1–25) and polytherapy (median: 6;
range: 3–19), and was different for children and adults only for poly-
therapy (median: 18 and 3 days). Seventeen patients (5.1%) needed
one or more day-hospital admissions. The median (range) number of
day-hospital admissions was 2 (1–15) andwas slightly different for pa-
tients on alternative monotherapy and those on polytherapy (median:
3 and 1.5). Forty-three patients (13.0%) had outpatient consultations.
The median (range) number of consultations was 1 (1–6) and did not
differ with treatment strategy and age (data not shown). Twenty-two
patients (10.6%) lost a total of 438 work-days and 41 (33.1%) a total of
691 school-days during the study. The likelihood of missing work or
school was not affected by treatment strategy or age.
One hundred adult patients on alternative monotherapy and 23 on
add-on therapy filled the QOLIE-31 inventory at baseline and at study
end. Their mean total scores were 58.9 and 57.7 at baseline and 61.9
and 60.7 at study end, respectively. However, repeated measures
ANOVA showed within-subject differences for the domains Seizure
worry, and Overall quality of life with no interaction between treatment
and time (Table 5).
4. Discussion
In this study, 72.2% of children and adults with epilepsy seen in
secondary and tertiary centers in whom a first monotherapy had
failed were switched to an alternative monotherapy, and a second
drug was added to the current treatment in only 27.8%. This prevail-
ing strategy can be explained by the merits of monotherapy, which
have been widely demonstrated [16], and is in keeping with the
therapeutic habits in other Mediterranean countries [7], with the rec-
ommendations in evidence-based guidelines [17–19] and with the
Table 4
Patients with adverse events occurring after study entry (MedDra categories) with relation to assigned treatment.
Adverse event Total
(326)
Alternative monotherapy
(235)
Add-on therapy
(91)
No. % No. % No. %
Blood and lymphatic system 1 0.3 1 0.4 – –
Cardiac 3 0.9 2 0.9 1 1.1
Ear and labyrinth 9 2.8 8 3.4 1 1.1
Eye 1 0.3 – – 1 1.1
Gastrointestinal 30 9.2 26 11.1 4 4.4
General and injection site 21 6.4 17 7.2 4 4.4
Hepatobiliary 1 0.3 1 0.4 – –
Immune system 3 0.9 3 1.3 – –
Infection and infestation 22 6.7 14 6.0 8 8.8
Injury, poisoning, and procedural complication 10 3.1 7 3.0 3 3.3
Investigations 4 1.2 3 1.3 1 1.1
Metabolism and nutrition 16 4.9 13 5.5 3 3.3
Musculoskeletal and connective tissue 1 0.3 – – 1 1.1
Neoplasm 2 0.6 2 0.9 – –
Nervous system 61 18.7 49 20.9 12 13.2
Psychiatric 26 8.0 19 8.1 7 7.7
Renal and urinary 7 2.1 3 1.3 4 4.4
Reproductive system and breast 5 1.5 5 2.1 – –
Respiratory, thoracic, and mediastinal disorders 24 7.4 18 7.7 6 6.6
Skin and subcutaneous tissue 11 3.4 8 3.4 3 3.3
Surgical and medical procedures 9 2.8 5 2.1 4 4.4
Vascular 5 1.5 4 1.7 1 1.1
AED, antiepileptic drug. None of the differences are statistically significant.
Table 5
QOLIE-31 scoresa in patients on alternative monotherapy and add-on therapy (N = 123).
Domain Basal score Final score Therapy effect
(between subjects)
p value
Time effect
(within subjects)
p value
Therapy × time
Monotherapy
Mean (95% CI)
Add-on therapy
Mean (95% CI)
Monotherapy
Mean (95% CI)
Add-on therapy
Mean (95% CI)
Social functioning 64.1 (59.2; 69.0) 60.0 (49.4; 70.5) 66.4 (61.8; 70.9) 62.8 (52.9; 72.9) 0.44 0.281 0.91
Medication effects 47.8 (42.0; 53.6) 55.8 (44.9; 66.7) 54.1 (47.8; 59.6) 59.5 (47.2; 71.9) 0.25 0.11 0.63
Cognitive 64.2 (59.5; 68.9) 62.6 (51.0; 74.2) 64.0 (59.6; 68.3) 62.1 (53.0; 71.2) 0.72 0.88 0.96
Energy fatigue 49.3 (45.6; 53.0) 53.7 (45.6; 61.8) 54.6 (51.0; 52.8) 55.9 (62.9; 49.0) 0.44 0.06 0.45
Emotional well-being 57.0 (53.3; 60.7) 61.6 (53.1; 70.1) 59.4 (56.0; 62.8) 63.1 (55.3; 71.0) 0.26 0.34 0.84
Overall quality of life 59.5 (56.3; 62.6) 55.5 (47.5; 63.6) 64.2 (61.2; 67.2) 62.3 (55.1; 69.5) 0.35 b0.01 0.62
Seizure worry 49.7 (44.2; 55.2) 38.6 (29.1; 48.0) 57.9 (52.9; 62.8) 50.1 (41.0; 59.3) 0.08 b0.01 0.51
Total score 58.9 (55.5; 62.3) 57.7 (46.8; 65.6) 61.9 (58.7; 65.1) 60.7 (54.2; 67.1) 0.73 0.07 1.00
The column “Therapy effect” indicates the level of significance of the difference between the two treatment strategies. The column “Time effect” indicates the level of significance of
the difference between baseline and the end of study (both treatments combined). The column “Therapy × time effect” indicates the interaction between treatment strategy and
time.
CI = confidence interval.
a A higher score indicates a better quality of life, in total and for each domain separately.
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opinions of US epilepsy experts [8]. Advocates of monotherapy claim
a lower incidence of adverse events, less potential for drug interac-
tion, better compliance, and reduced costs. Our data do not support
these claims because the direct, indirect, and intangible costs (mea-
sured respectively by the number of consultations and hospital ad-
missions, the number of work or school absences, and the HRQOL
scores) were similar in the two treatment groups, and the overall in-
cidence of adverse events was slightly lower in patients receiving a
combination therapy. In addition, the adverse events reported by
the two treatment cohorts were similar as regards severity, attribu-
tion to drug, and outcome.
These findings are in keeping with randomized trials comparing
mono- and polytherapy, which showed a lower cumulative number of
adverse effects in patients on polytherapy [6] and fewer polytherapy
patients withdrawing from the study because of adverse effects [20].
This slight (nonsignificant) difference cannot be explained by the
lower target daily doses in patients receiving add-on therapy than
those switched to alternative monotherapy, as this was true only for
lamotrigine and oxcarbazepine, two drugs for which the incidence
ratio of adverse events was among the lowest. One possible explanation
is the absence of cumulative (adverse) effects of antiepileptic drugs
when given in combination. An alternative explanation is the preva-
lence of concomitant disorders, which was higher in patients switched
to alternative monotherapy (34.7%) than in those receiving add-on
therapy (20.6%).
Valproate was the commonest drug at study entry, followed by car-
bamazepine, phenobarbital, and oxcarbazepine. Topiramate was the
commonest drug given as alternative monotherapy, followed by carba-
mazepine, valproate, and oxcarbazepine. Topiramatewas also preferred
for add-on therapy, followed by levetiracetam. Minor differences were
seen between children and adults. The physicians' attitude emerging
in this study shows that after failure of a first monotherapy, a second-
generationAED ismore likely to be chosen. Drug choice perhaps reflects
each physician's experience with each compound and the different
spectra of approved indications for each AED at the time of study entry.
The incidence of adverse events was higher in children than in
adults and varied across drugs, with phenobarbital and clobazam at
one extreme and ethosuximide at the other. Differences did not attain
statistical significance, however, possibly because of the small num-
bers within subgroups.
Retention time and 12-month chance of seizure remission were
similar in the two groups. Evenwith differences in remission rates com-
pared to other reports [5,6,20], our findings confirm the results of ran-
domized trials [6,20] and suggest that when a first monotherapy fails,
the probability of subsequent success is largely independent of treat-
ment strategy.
Interestingly, children had a lower retention time than adults,
irrespective of treatment strategy. This might be explained by the
greater alarm evoked in parents/caregivers by a lack of effect or poor
tolerability of treatment.
The study has some strengths and several limitations. The major
strength is the sample size. Other observational studies which assessed
the effects of substitution therapy and add-on therapy were done in
small series of patients [5]. A second strength is the nationwide distribu-
tion of the participating centers which, to some extent, represent cur-
rent clinical management of epilepsy in Italy. A third strength is the
prospective study design, with predefined assessment and control of
all the study variables.
The main shortcomings of this study include the nonrandomized
nature of the design, the uncontrolled drug choice, and the lack of
blinding procedures, which prevent comparisons across drugs and
drug combinations. However, this was a pragmatic, prospective, ob-
servational investigation and, as such, treatment choice and (adverse)
effects were reported with knowledge of the underlying treatment
and in line with clinical practice in Italy. Another probably relevant
limitation is the sample size, which may have been too small to detect
differences in light of the different proportions of patients assigned to
monotherapy and add-on therapy. In addition, outcome measures
like number of cases admitted to hospital or outpatient consultations
and absence fromwork or school were so infrequent as to prevent de-
tection of even a major difference. By the same token, the number of
patients interviewed for the assessment of quality of life was perhaps
too small to detect differences in the scores. Then, it is to be assumed
that the participating investigators used their clinical judgment to de-
termine the best therapeutic approach (add-on vs. switch) for each
individual patient, thus ensuring a beneficial treatment outcome. Be-
cause of individualization of the treatment and trial-related lack of
randomization, a true interpretation of the risk and benefits of both
treatment approaches cannot be derived from this study.
In conclusion, the preferred use of alternative monotherapy when
the first treatment fails does not necessarily lead to a better outcome,
in terms of seizure recurrence and adverse treatment effects. Alterna-
tive monotherapy should be weighed against polytherapy in terms of
expected efficacy, tolerability, and costs for each individual patient.
Conflict of interest
Dr. Millul has received personal compensation for consultancy by
Novartis Vaccines. Dr. Iudice has received personal compensation for
consultancy by Janssen-Cilag. Drs. Adami and Porzio are employees of
Janssen-Cilag. Dr. Mattana has no conflicts of interest. Dr. Beghi serves
on the editorial advisory boards of Epilepsia, Amyotrophic Lateral
Sclerosis, Clinical Neurology & Neurosurgery, and Neuroepidemiology;
has received money for board membership by VIROPHARMA and
EISAI; has received funding for travel and speaker honoraria from
UCB-Pharma, Sanofi-Aventis, GSK; and has received funding for educa-
tional presentations from GSK.
Ethical publication
We confirm that we have read the Journal's position on issues in-
volved in ethical publication and affirm that this report is consistent
with those guidelines.
Acknowledgments and funding
The study was sponsored by Janssen-Cilag SpA.
References
[1] Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in pa-
tients with epilepsy. Epilepsia 1979;20:729–37.
[2] Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy:
results from the National General Practice Study of Epilepsy. Lancet 1995;346:140–4.
[3] Collaborative Group for the Study of Epilepsy. Prognosis of epilepsy in newly re-
ferred patients: a multicenter prospective study of the effects of monotherapy
on the long-term course of epilepsy. Epilepsia 1992;33:45–51.
[4] Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med
2000;342:314–9.
[5] Deckers CLP, Genton P, Sills GJ, Schmidt D. Current limitations of antiepileptic drug
therapy: a conference review. Epilepsy Res 2003;53:1–17.
[6] Beghi E, Gatti G, Tonini C, ben-Menachem E, Chadwick DW, Nikanorova M, et al.
Adjunctive therapy versus alternative monotherapy in patients with partial
epilepsy failing on a single drug: a multicentre, randomized, pragmatic controlled
trial. Epilepsy Res 2003;57:1–13.
[7] Baldy-Moulinier M, Covanis A, D'Urso S, Eskazan E, Fattore C, Gatti G, et al. Ther-
apeutic strategies against epilepsy in Mediterranean countries: a report from an
international collaborative survey. Seizure 1998;7:513–20.
[8] Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion,
2005. Epilepsy Behav 2005;7:S1–S64.
[9] Kwan P, Brodie MJ. Drug treatment of epilepsy: when does it fail and how to op-
timize its use? CNS Spectr 2004;9:110–9.
[10] Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology
2002;58(Suppl. 5):S2–8.
[11] Commission on Epidemiology and Prognosis, International League Against Epilepsy.
Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993;34:592–6.
[12] Commission on Classification and Terminology of the International League Against
Epilepsy. Proposal for revised clinical and electroencephalographic classification of
epileptic seizures. Epilepsia 1981;22:489–501.
499A. Millul et al. / Epilepsy & Behavior 28 (2013) 494–500
Author's personal copy
[13] Commission on Classification and Terminology of the International League Against
Epilepsy. Proposal for revised classification of epilepsies and epileptic syndrome.
Epilepsia 1989;30:389–99.
[14] Medical dictionary for regulatory activities. Version 14.0. Northrop Grumman
Corporation; 2011.
[15] Beghi E, Niero M, Roncolato M. Validity and reliability of the Italian version of the
Quality-of-Life in Epilepsy Inventory (QOLIE-31). Seizure 2005;14:452–8.
[16] Beghi E, Perucca E. The management of epilepsy in the 1990s: acquisitions, uncer-
tainties, and perspectives for future research. Drugs 1995;49:680–94.
[17] National Institute for Clinical Excellence. Newer drugs for epilepsy in adults.
www.nice.org.uk/Docref.asp?d=110081 [accessed Aug 31, 2004].
[18] National Institute for Clinical Excellence. Newer drugs for epilepsy in children.
www.nice.org.uk/Docref.asp?d=113359 [accessed Aug 31, 2004].
[19] Scottish Intercollegiate Guidelines Network. Diagnosis and management of epi-
lepsy. www.sign.ac.uk/pdf/sign70.pdf [accessed July 31, 2004].
[20] Deckers CLP, Hekster YA, Keyser A, van Lier HJJ, Meinardi H, Renier WO. Mono-
therapy versus polytherapy for epilepsy: a multicenter double-blind randomized
study. Epilepsia 2001;42:1387–94.
500 A. Millul et al. / Epilepsy & Behavior 28 (2013) 494–500
